Avi Eliassaf

Anima Biotech, Inc. develops translation control therapeutics, a new class of drugs that specifically control protein translation as a novel strategy against hard and undruggable targets. The firm?s platform combines new biology with proprietory image analysis and big data software. The company was founded Yochi Slonim and Zeev Smilansky and is headquartered in Bernardsville, NJ.

Anima Biotech, Inc. develops translation control therapeutics, a new class of drugs that specifically control protein translation as a novel strategy against hard and undruggable targets. The firm?s platform combines new biology with proprietory image analysis and big data software. The company was founded Yochi Slonim and Zeev Smilansky and is headquartered in Bernardsville, NJ.

Anima Biotech, Inc. develops translation control therapeutics, a new class of drugs that specifically control protein translation as a novel strategy against hard and undruggable targets. The firm?s platform combines new biology with proprietory image analysis and big data software. The company was founded Yochi Slonim and Zeev Smilansky and is headquartered in Bernardsville, NJ.

Anima Biotech, Inc. develops translation control therapeutics, a new class of drugs that specifically control protein translation as a novel strategy against hard and undruggable targets. The firm?s platform combines new biology with proprietory image analysis and big data software. The company was founded Yochi Slonim and Zeev Smilansky and is headquartered in Bernardsville, NJ.

Anima Biotech, Inc. develops translation control therapeutics, a new class of drugs that specifically control protein translation as a novel strategy against hard and undruggable targets. The firm?s platform combines new biology with proprietory image analysis and big data software. The company was founded Yochi Slonim and Zeev Smilansky and is headquartered in Bernardsville, NJ.